Evidence map›Paper›PMID 29385199›Full record

ArticlePloS one2018

Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm.

Christiane Schaefer, Nikhil Mallela, Jochen Seggewiß, Birgit Lechtape, Heymut Omran, Uta Dirksen, Eberhard Korsching, Jenny Potratz

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. A Manual for Genome and Transcriptome Engineering.IEEE reviews in biomedical engineering · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Identification of Biomarkers for Osteosarcoma Based on Integration Strategy.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christiane SchaeferPediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
Nikhil MallelaInstitute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany.
Jochen SeggewißInstitute of Human Genetics, University Hospital Münster, Münster, Germany.
Birgit LechtapePediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
Heymut OmranGeneral Pediatrics, University Hospital Münster, Münster, Germany.
Uta DirksenDepartment of Hematology and Oncology, Pediatrics III, West German Cancer Center, German Cancer Consortium (DKTK) Center Essen, University Hospital Essen, Essen, Germany.
Eberhard KorschingInstitute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany.
Jenny PotratzPediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-1327-5981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the search for novel therapeutic targets, RNA interference screening has become a valuable tool. High-throughput technologies are now broadly accessible but their assay development from baseline remains resource-intensive and challenging. Focusing on this assay development process, we here describe a target discovery screen using pooled shRNA libraries and next-generation sequencing (NGS) deconvolution in a cell line model of Ewing sarcoma. In a strategy designed for comparative and synthetic lethal studies, we screened for targets specific to the A673 Ewing sarcoma cell line. Methods, results and pitfalls are described for the entire multi-step screening procedure, from lentiviral shRNA delivery to bioinformatics analysis, illustrating a complete model workflow. We demonstrate that successful studies are feasible from the first assay performance and independent of specialized screening units. Furthermore, we show that a resource-saving screen depth of 100-fold average shRNA representation can suffice to generate reproducible target hits despite heterogeneity in the derived datasets. Because statistical analysis methods are debatable for such datasets, we created ProFED, an analysis package designed to facilitate descriptive data analysis and hit calling using an aim-oriented profile filtering approach. In its versatile design, this open-source online tool provides fast and easy analysis of shRNA and other count-based datasets to complement other analytical algorithms.

Indexed as

Gene LibraryAlgorithmsCell Line, TumorComputational BiologyDrug DiscoveryDrug Evaluation, PreclinicalHEK293 CellsHigh-Throughput Nucleotide SequencingHumansLentivirusRNA InterferenceRNA, Small InterferingSarcoma, EwingSequence Analysis, RNAWorkflowRNA, Small Interfering

Identifiers

PMID29385199
PMCPMC5792015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.